Introduction
that concentrates fall under the scope of Community Directive 93/42/EEC on Medical Devices.
Devices are divided into four classes (I, IIa, IIb and The introduction of Community Directive 93/42/EEC III ), depending on their intended use and on the [1] on Medical Devices has produced a major change hazards that the intended use generates. It is important in the philosophy related to safety and performance to underline that, since the intended use of the device evaluation of medical devices.
is totally at the discretion of the manufacturer, which, The Directive, published in 1993, was introduced on as we will discuss later, is the sole agent responsible a voluntary basis at the beginning of 1995, and it is due to become mandatory on June 14, 1998. According for assigning to its products the performance limits it to the rules of the European Union, all 15 Member feels appropriate, the classification of medical devices D. Pirovano 22 tion, in combination with other devices as indicated device, having a certain declared performance, is suitable for performing a specific therapy or diagnosis on by the manufacturer in the accompanying documentation and within the limits of performance indicated by a specific patient: if a device, in spite of its 'limited' declared performances, is able to save even only one the manufacturer in the accompanying documentation.
The user of medical devices must therefore pay the life, it must be available to doctors. utmost attention to the content of the accompanying documentation ( labels and instructions for use) which Particular remarks applicable to on-line HDF is the only valid document to determine whether a given device is suitable for the specific treatment he intends to deliver to a patient. Consequently, in the For the sake of this part of the article, we will assume that on-line HDF is a combination of an electromedical event that he reads that the device is not intended to be used in a certain way, under certain circumstances device, of some disposables and of the concentrates.
From what has been said above, the three componor with other specific devices, he must refrain for using it for that treatment or, indeed, not buy it.
ents should have been indicated by their manufacturers as being appropriate for use with each other, either by To use an example, if a manufacturer claims that its electromedical device can be operated safely with a an explicit reference, or by referring to the characteristics necessary for the correct use of the different supply voltage between 210 and 230 V and the hospital buyer knows that its electrical supply may have fluctu-devices.
While the application of Community Directive ations outside that range, he should refrain from buying the device or introduce appropriate measures 93/42/EEC on Medical Devices to the 'machine' part of the system and to the disposable part of the system for maintaining the voltage fluctuation within the limits specified by the manufacturer.
does not pose particular problems as compared with any other medical device, the concentrates do need The user must at all times bear in mind that the CE marking ensures safety only when the device is used some clarification.
Making an analogy with the example of the elecas intended by its manufacturer and as indicated in the accompanying documentation; any other 'intended tromedical device rated for 210-230 V mentioned above, the concentrates for on-line HDF should be use' suggested verbally by the manufacturer or its sales force has not been the subject of appropriate evaluation supplied with the exact indication on the quality of the water which must be used. In doing so, the manufrom the safety stand point, therefore the device used outside the specification given by its manufacturer in facturer assumes the responsibility of ensuring under what circumstances the concentrate and, consequently, the accompanying documents does not bear the CE marking legally.
the entire system are safe and perform as specified. Any difference in the characteristics of the water results Another important meaning of the CE marking is that the manufacturer ensures, by affixing it to the in the use of the device in a manner which has not been subject to appropriate verification. In other product, that the performance claimed for that product can be attained.
words, the combination of the various devices and, in particular, the concentrates, when used with a water It is worth, here, enlarging on this concept of performance which has been one of the most contentious which does not have the characteristics indicated by the manufacturer, becomes a 'new' device since the issues during the development and negotiation of the Directive.
intended use is changed; consequently, in order to bear the CE marking of conformity to Community Directive Previous legislation, as well as the Medicinal Products legislation and the present American Food 93/42/EEC on Medical Devices, it should be subject to a new conformity assessment procedure. and Drug Administration regulation were/are basing the evaluation of a product on its efficacy, meaning by Continuing this analogy, this means that the concentrates should be used by a given user only when, for this the ability of the product to treat certain diseases, handicaps or injury.
example, the user is capable of exerting an appropriate and continuous control of the characteristics of the The evaluation of efficacy is often made on the assumption that, if alternative methods are available water, used to dilute the concentrates, which have to be maintained within the limits specified by the manuand the new device does not show, in the reviewer's opinion, a substantial improvement, the device does facturer of the medical device. In order to exert such control of the water, the user should have a structure, not have sufficient efficacy to justify its presence on the market. Since this kind of judgment is highly appropriately organized, which allows him to take full responsibility for this issue. If the user fails to be able subjective, the time necessary for reviewing a device becomes quite long, and final approval is far from to do so, he should choose other HDF systems rather than risk using the device outside its specifications, certain.
In the opinion of the European Commission and since this would put the entire responsibility for any accident on his shoulders. the EU Member States, this is not exactly the correct way of operating a regulation in a sector which is Let us now briefly discuss an aspect related to the use of on-line HDF as opposed to traditional HDF continuously and rapidly evolving.
In the opinion of the European legislator, the doctor which shows quite explicitly the differences between the traditional regulation and the new one. As is is the only one responsible to decide whether or not a Regulatory issues for on-line HDF 23 known, the basic difference lies in the fact that, as 'devices must be designed and manufactured in such a previously mentioned, according to the present inter-way that, when used under the conditions and for the pretation of the Medical Devices Directive, the concen-purpose intended, they will not compromise the clinical trates used in on-line HDF are considered as medical condition or the safety of patients … provided that devices, whereas the solutions used with traditional any risk associated to their use constitutes acceptable HDF are considered as medicinal products and are risks when weighted against the benefits to the patient covered by a Pharmacopoeia Monograph. This latter and are compatible with a high level of protection of circumstance, in spite of the well known saying that health and safety'. 'something which is regulated by the pharmaceutical Help is given to the manufacturers, within the directlaw is safer than a medical device', might lead to ive, by the obligation to perform a so-called risk potentially greater problems than those with on-line analysis. For this risk analysis, which is compulsory HDF. In fact, the limits given by the Pharmacopoeia, for devices of all classes, the manufacturer is guided which were stated many years ago, do not consider through the characteristics of its device in an organized the developments in the HDF technique which now-manner, thus identifying all hazards related to the use adays requires >10 l of liquid to be administered to of its device and analysing the appropriate methods to the patient. As a result of this, a solution which reduce the related risks. conforms perfectly to the upper limit for endotoxins
In other words, this means that, in spite of any given in the Pharmacopoeia might result in total deliv-indication given in any Standard or in a ery of endotoxins to the patient of 10 times more Pharmacopoeia Monograph, the manufacturer has to than the maximum bearable. It is only thanks to the take all necessary steps to ensure that its product is self-discipline of the manufacturers of these products, safe for the intended use and, consequently, assume who stay well under the limits imposed by the all responsibilities in this sense without 'hiding' himself Pharmacopoeia, that this circumstance does not arise. behind the blind conformity to such Standards or On the other hand, the manufacturer of the device Pharmacopoeia Monographs. 'concentrate' must, in order to be able to affix the CE marking, demonstrate under its full responsibility (and under the control of an official testing body, the Reference so-called Notified Bodies) that the device is able to fulfil, for example, Essential Requirement no. 1 of 1. Community Directive 93/42/EEC on Medical Devices. Official
